Latest news

• NHS chief pledges CAR-T support, but asks for pricing restraint

  primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL).

• Novartis files CAR-T therapy CTL109 in Europe

  Kite was the first to file its new therapy in Europe, seeking approval in August for DLBCL, transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) in adults ineligible

• Kite starts EU trial of lead CAR-T therapy

  Adult patients with DLBCL, PMBCL and TFL will be enrolled in the trial. ... Kite is currently enrolling adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and transformed follicular

• Kite files first CAR-T candidate in Europe

  cell lymphoma (PMBCL) who are ineligible for autologous stem cell transplant.

• Kite Pharma soars after positive CAR-T data in lymphoma

  B-cell lymphoma (PMBCL) - on the strength of the trial results.